Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Author:
Publisher
John Wiley & Sons, Ltd
Link
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003370.pub2/epdf/full
Reference94 articles.
1. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer;Alonso-Munzo;Oncology,1988
2. Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer;Bezwoda;Oncology,1998
3. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma;Bonneterre;Cancer,2001
4. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study;Bonneterre;Journal of Clinical Oncology,2000
5. Advanced breast cancer updates on anastrozole versus tamoxifen;Nabholtz;Journal of Steroid Biochemistry and Molecular Biology,2003
Cited by 97 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The relationship between anxiety and vaginal-related sexual health in postmenopausal breast cancer survivors on aromatase inhibitors therapies: a cross sectional study;Breast Cancer Research and Treatment;2023-05-24
2. Consideration of breast cancer subtype in targeting the androgen receptor;Pharmacology & Therapeutics;2019-08
3. Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study;BMC Cancer;2019-06-21
4. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm;Asia-Pacific Journal of Clinical Oncology;2018-10
5. An update on treatment for post-menopausal metastatic breast cancer in elderly patients;Expert Opinion on Pharmacotherapy;2018-03-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3